http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Edwards Lifesciences To Host Earnings Conference Call On January 30, 2020
-
Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference
-
Edwards Lifesciences (EW) Reaffirms FY19 Guidance, Offers FY20 Guidance at Investor Conf.
-
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
-
Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe
-
Pre-Open 10/24: (TSLA) (AYR) (PYPL) Higher (ACOR) (TWTR) (TXMD) Lower (more...)
-
Edwards Lifesciences Reports Third Quarter Results
-
Edwards Lifesciences To Host Earnings Conference Call On October 23, 2019
-
Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients
-
Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare Conference
-
Edwards Lifesciences (EW) Announces SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
-
Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
-
Edwards Lifesciences Reports Second Quarter Results
-
Edwards Lifesciences To Host Earnings Conference Call On July 23, 2019
-
Edwards Comments On Updated TAVR National Coverage Determination
-
Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
-
Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation
-
Edwards Announces Milestones For Transcatheter Mitral Program
-
Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020
-
Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue
-
Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
-
Edwards Lifesciences Reports First Quarter Results
-
Edwards Lifesciences (EW) Completes Acquisition of CASMED (CASM)
-
Edwards Lifesciences Completes Acquisition of CASMED
-
Edwards Lifesciences To Host Earnings Conference Call On April 23, 2019
-
Edwards Lifesciences (EW) SAPIEN 3 Valve Proves Superior To Surgery in Latest Trial
-
Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial
-
Edwards Lifesciences (EW) announced two strategic transactions involving companies with structural heart disease tech
-
Edwards Lifesciences Announces Strategic Investments
-
Edwards Lifesciences (EW) PASCAL Transcatheter System Receives CE Mark
-
Edwards PASCAL Transcatheter System Receives CE Mark
-
Edwards Lifesciences (EW) to Acquire CASMED (CASM) for $2.45/Share
-
Edwards Lifesciences Enters Into Agreement To Acquire CASMED
-
Boston Scientific Announces Results For Fourth Quarter And Full Year 2018
-
Edwards Lifesciences Reports Fourth Quarter Results
-
Edwards Lifesciences To Host Earnings Conference Call on January 31, 2019
-
Boston Scientific (BSX) and Edwards Lifesciences (EW) Agree to Settle Litigation
-
Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
-
Edwards Lifesciences (EW) Reports FDA Approval for SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval
-
Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval
-
Edwards Comments On U.S. Court Decision
-
Edwards Lifesciences (EW) Offers Financial Guidance
-
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
-
Edwards Lifesciences (EW) Receives FDA Clearance For HemoSphere Platform With Intelligent Decision-Support Tools
-
Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support Tools
-
Edwards Lifesciences (EW) SAPIEN 3 Ultra Transcatheter Heart Valve Receives CE Mark
-
Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives CE Mark
-
Edwards Lifesciences Reports Third Quarter Results
-
Edwards Lifesciences (EW) Releases Statement on German Court Decision to Grant Boston Scientific Corp. (BSX) Prelim. Injunction on Edwards SAPIEN 3 Ultra Valve in Germany
-
Edwards Comments On German Court Decision

